ADVA
12.1.2021 09:02:30 CET | Business Wire | Press release
ADVA (FSE: ADV) today announced the expansion of its Ensemble Harmony Ecosystem to include disaggregated packet networking. Alpha Networks, Delta, Edgecore Networks and UfiSpace have all joined the open multi-vendor program. Each new member offers high-performance hardware platforms proven to interoperate with ADVA’s Ensemble Activator, a carrier-grade network operating system (NOS) specifically designed for white box switches. The Ensemble Harmony Ecosystem helps to accelerate softwarization and virtualization by offering service providers and enterprises access to the industry’s most comprehensive portfolio of flexible and disaggregated networking technologies. The addition of white box switch suppliers means it now delivers even more value to customers and helps to further simplify their transition to software-driven networking.
“Since the inception of NFV, our Ensemble Harmony Ecosystem has led the way, delivering unparalleled variety and choice of onboarded virtual network functions (VNFs). Now we’re opening up this unique multi-vendor environment to include some of the industry’s most innovative hardware suppliers, ensuring easy interoperability and new levels of collaboration for the rapid development of future services,” said James Buchanan, GM, Edge Cloud, ADVA. “This latest expansion of Ensemble Harmony will help more customers to realize the true value of virtualization and disaggregated packet networking as a catalyst to openness, componentized systems and innovation at the speed of software. The journey to white box switches and servers and software-driven networking is now simpler and more cost-efficient than ever before. ADVA is now the clear leader in network operating systems for white boxes.”
With the addition of leading hardware suppliers, ADVA’s open Ensemble Harmony Ecosystem provides everything service providers and businesses require to harness the power of disaggregated networking. Each of the new member companies offers highly efficient white box technology proven to interoperate successfully with ADVA’s Ensemble Activator , the first NOS designed for bare-metal switches. Already successful in trials with multiple global mobile network operators, including Telefónica and Vodafone, Ensemble Activator is the market’s most versatile operating system for disaggregated cell site gateways. When combined with Ensemble Harmony partner hardware, it offers new levels of agility and freedom and a clear route to cost-effective mass rollout of 5G services over large, geographically dispersed, multi-vendor networks.
“We’re excited to be among the first hardware partners to be welcomed into the Ensemble Harmony Ecosystem. It’s a community that shares our dedication to openness and interoperability. Together we can remove even more of the shackles of single-vendor proprietary solutions,” commented George Tchaparian, CEO, Edgecore Networks. “Today’s customers refuse to accept the constraints, the complexity and the expense of closed hardware and software systems. They demand the freedom to build scalable, cost-effective infrastructure on best-in-class open products and solutions. That’s why we’re working closely with Ensemble Harmony software partners, helping operators make the leap to virtualization and harness the benefits of openness and disaggregation.”
“ADVA’s Ensemble Harmony Ecosystem is a pillar of the open environment. Its philosophy is perfectly aligned with our own focus on disaggregation and open networking. What’s more, by collaborating with ADVA, we can add more value to our innovations and increase speed to market for our customers,” said Vincent Ho, CEO, UfiSpace. “We’ve been driving the next generation of open networking solutions with our carrier-grade disaggregated white box and network cloud solutions. Now, as part of Ensemble Harmony, we can give even more customers the freedom to choose from a wide range of fully integrated software and hardware technologies and select the ideal disaggregated solution for their business needs.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210112005057/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 09:00:00 CEST | Press release
The combination unites Pelago Bioscience’s industry-leading and proprietary cellular target engagement capabilities with RG Discovery’s deep medicinal chemistry and custom synthesis expertise - enabling customers to advance drug discovery programs across the full design-make-test-analyze-(DMTA) cycle with a single specialist partner. Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discover
LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 08:10:00 CEST | Press release
AI-native operations model enables enterprises to move from reactive service delivery to intelligent, outcome-driven managed services LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across sys
Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release
Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A
Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release
Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom